COVID-19:富士フイルム、Eli Lillyから受託:抗体医薬の原薬製造(動画):  COVID-19: Contracted by Fujifilm、Eli Lilly: Substance for antibody drugs: COVID-19:Fujifilm和礼来公司签约:抗体药物的原料药生产

COVID-19:富士フイルム、Eli Lillyから受託:抗体医薬の原薬製造(動画): 
COVID-19: Contracted by Fujifilm、Eli Lilly: Substance for antibody drugs:
COVID-19:Fujifilm和礼来公司签约:抗体药物的原料药生产

ー低・中所得国への普及を目指すー

富士フイルム:FUJIFILM Diosynth Biotech(FDB)

Eli Lilly社から、新型コロナウイルス感染症向け、抗体医薬品の原薬製造を受託しました。

FUJIFILM Diosynth Biotech(FDB):

2021年4月より、デンマーク拠点にて製造を開始します。

Eli Lilly社のCOVID-19向け抗体医薬品を、低・中所得国への普及に貢献します。

富士フイルム [日本]

https://www.fujifilm.com/jp/ja/news/list/5537

FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody

for Low- and Middle-Income Countries

ILLERØD, Denmark,
October 8, 2020 —

FUJIFILM Diosynth Biotechnologies,
a world leading Contract Development and Manufacturing Organization (CDMO)
for biologics, viral vaccines and viral vectors,

today announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP* facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator.

The commercial manufacturing falls under the agreement between Lilly and the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator,

to supply potential Lilly therapeutic antibodies for the prevention and treatment of COVID-19.

The Therapeutics Accelerator is an initiative launched by

  1. the Gates Foundation,
  2. Wellcome,
  3. Mastercard

to speed up the response to the COVID-19 pandemic by identifying, assessing, developing, and scaling up treatments

Fujifilm Global

https://www.fujifilm.com/news/n201009_02.html